Tzield® (teplizumab-mzwv)
| Full Name | Tzield® (teplizumab-mzwv) |
| Drug | Tzield |
| Manufacturer | Sanofi |
| Route of Administration | Intravenous |
| Site of Care | Home or Healthcare Facility |
| Approved Indication | Delay the onset of Stage 3 type 1 diabetes (T1D) in adults and pediatric patients aged 8 years and older with Stage 2 T1D |
| Disease | Type 1 Diabetes (T1D) |
| Therapeutic Area | Endocrinology & Bone Specialty |
| Enrollment Form Link | Tzield Enrollment Form |
| Phone Number | 800-670-5321 |
| Fax Number | 877-655-4364 |
| Product Website | tzield.com |